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Abstract
Background: One of the most important vulnerabilities falling the efficacy of recombinant human growth
hormone (r-hGH) treatment is low adherence especially in young patients. This study was planned to describe the
correlation between r-hGH treatment efficacy and adherence in real-life setting using easypod™.
Methods: Forty patients younger than 18 years, affected by a clinical condition in which r-hGH is available and
treated with r-hGH easypod™, were enrolled in a retrospective, observational, real-world data, monocentric trial. The
study design provided the retrospective collection of records collected by a questionnaire proposed to the patients
and their parents and compared with registered data by the new generation electronic device r-hGH easypod™.
Number of injections and doses were collected and used to assess the percentage of administered GH doses to
measure treatment adherence. The r-hGH treatment efficacy was evaluated comparing standard deviation score for
height (SDS) between baseline and follow-up visit, according to clinical practice.
Results: The mean treatment adherence was 92.20% and it was inversely related to patients’ age (R = − 0.358, p = 0.
023), and significantly higher in the sub-group of patients with age between 10 and 13 years. Treatment adherence
showed an inverse correlation with the years of therapy (R = − 0.453, p = 0.003) and with the number of r-hGH
administrations (R = − 0.392, p = 0.012). However, the height increase did not reach a significant correlation with
treatment adherence (R = − 0.067, p = 0.683).
Conclusions: Children and adolescent patients with GH deficiency due to different clinical conditions show high
adherence to r-hGH treatment tested by easypod™. Easypod™ could be used as an important device to control
patients’ adherence in daily treatment for chronic diseases with expensive drugs.
Keywords: R-hGH, Easypod™, Growth hormone deficiency, Treatment adherence, Small for gestational age, Turner
syndrome
Background
Recombinant human growth hormone (r-hGH) is widely
employed for treatment of several growth disorders since
1985 [1, 2]. In Italy, r-hGH is indicated in GH deficiency
(GHD), Turner syndrome (TS), short stature associated
with SHOX aploinsufficiency, short children born small
for gestational age (SGA), chronic renal failure (CRF)
and Prader-Willi syndrome [3]. This treatment is pri-
marily used in childhood and adolescence and the
growth improvement measurement is generally used to
evaluate therapy efficacy. Although it is well known that
an early r-hGH treatment start improves the final height,
the lack of treatment adherence could hamper the
growth potential [4, 5]. Thus, treatment adherence re-
mains the most important factor influencing the suc-
cessful outcomes, as well as in the vast majority of
chronic therapies [6]. Indeed, low adherence is a signifi-
cant factor determining reduced growth gain with
r-hGH treatment and increased health costs [7].
Chronic long-term treatments are generally characterized
by low adherence. Once more, r-hGH treatment is often
burdened by suboptimal adherence, especially in paediatric
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population. Several studies reported that up to half patients
are generally not fully adherent [8]. This therapy requires
daily subcutaneous injections and children often have a sig-
nificant load related to the daily administration of r-hGH,
missing the final goal of benefits in height [4, 5]. This dis-
crepancy, generally called “treatment fatigue”, could nega-
tively influence treatment adherence especially in children
and adolescents [9]. Several strategies have been proposed
so far in the literature to improve patients’ adherence and
enhance self-administration [8]. The improvement device
simplicity, convenience, appropriate education and training
of both patients and parents are mandatory to increase the
adherence [10]. However, the main clinical challenge re-
mains the impossibility to accurately measure the treatment
adherence [9, 11]. The accurate monitoring of the therapy
remains the main objective of new therapeutic devices [6].
Indeed, a complete evaluation of patients’ adherence al-
lows the clinicians to exclude poor adherence from the
possible reasons for sub-optimal growth response, driving
further treatment adjustment and exact interval among
follow-up visits.
Currently, several devices are commercially available and
r-hGH compounds have been improved with the replace-
ment of traditional syringes with needles with more
user-friendly devices [12]. These innovations have sought to
improve adherence by simplifying injection, reducing pain,
improving convenience and patient acceptability [13–16].
The electronic auto-injector device, easypod™, owns several
features which improve the device simplicity, comfort and
convenience, such as pre-set dosing, adjustable injection set-
tings, an electronic skin sensor able to distinguish the skin
of the patient from skin of others [17]. Moreover, easypod™
allows an accurate surveillance of treatment adherence, an
injection diary that automatically registers injection times
[17]. These data are available by patients and by the clini-
cians who follow the patients using a remote access [17].
Despite these efforts to reduce treatment discomforts and
challenges, the adherence to r-hGH treatment remains sub-
optimal in paediatric population, due to lack of a reliable
method able to comprehensively evaluate all possible causes
of poor adherence. The primary objective of this study was
the evaluation of r-hGH treatment adherence, using easy-
pod™ in children and adolescents during follow-up. Second-
ary endpoints were: the study of r-hGH efficacy in growth
improvement and height gain, considering both efficacy and
treatment adherence; to limit waste involved in expensive
therapies for the national health system; to optimize GH
therapy, improving the quality of patient assistance.
Methods
Study design
A retrospective, observational monocentric study based
on real-world data was carried out at the Paediatric
Clinic of the “G. Di Cristina” Children Hospital, ARNAS,
Palermo, Italy. All children and adolescents treated with
r-hGH from 2009 to 2016, using the electronic device
easypod™ were enrolled. Accordingly, r-hGH treatment
and dosage were provided following the clinical practice.
Patients with age below 18 years and a confirmed diag-
nosis of GH deficiency were enrolled, using two GH
stimulating tests executed at least at the interval of 1
month. Moreover, patients in which the r-hGH treat-
ment is approved were enrolled, such as isolated GH
deficiency, SGA, chronic renal failure and Turner
syndrome.
Both patients and their parents were informed about
the study scope and design. The informed consent was
provided to all patients and parents.
The study design provided the retrospective collection
of data recorded in the electronic device easypod™ from
2009 to 2016. The number of injections and the doses
were collected and analysed to calculate treatment ad-
herence percentage, using the following formula:
number of injections in the time−frame
number of injections expected in the same time−frame
 100:
Data were collected at baseline, i.e. before the treat-
ment start, and after appropriate follow-up, which was
variable for each patient, according to clinical practice.
Satisfaction questionnaire
A simple questionnaire of satisfaction was created ad
hoc evaluating the several items related to the treat-
ment (Table 1).
Anthropometrical parameters
The treatment efficacy was evaluated using the height
gain at the follow-up, considering the change in the
standard deviation (SD) of height from baseline.
Height was measured using Harpenden stadiometer
(Crosswell, Crymych, Pembs., SA41 3UF, UK). Percentile
Table 1 Questionnaire of satisfaction created ad hoc for the
trial
1 Quality and completeness information received
prior to treatment
2 Degree of parental education
3 Ease of use of easypod™
4 Pain related to injection
5 Person who perform the injection
6 Number of injections not performed in the
last moth
7 Reasons of low adherence
8 Whether patients refuse one or more of the
sites proposed for injections
9 Whether patients had ever thought to abandon
the therapy
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of height was evaluated using the Italian growth charts
available in the literature [18], growth velocity using
Tanner’s charts [19], whereas skeletal age through the
Greulich-Pyle method [20].
Hormonal measurements
IGF-1 serum levels were measured to evaluate the treat-
ment efficacy through a single radio-immunological
assay. Thyroid stimulating hormone (TSH), free-triiod
iothyronine (fT3), free-tetraiodiothyronine (fT4), insulin,
glucose, blood counts and liver and renal function were
measured to consider the treatment safety.
Statistical analysis
Patients were classified by gender, age and treat-
ment duration.
Correlation between the treatment adherence and pa-
rameters collected was performed using Pearson’s correl-
ation. Treatment efficacy was evaluated considering the
SD of height at baseline and at the end of follow-up.
Sub-groups analyses were performed dividing patients
according age in three groups: 14 patients were between
age 5 and 9 years, 15 patients were between age 10 and
13 years, and 11 patients were with age above 14 years.
Moreover, patients were divided in group A (seven ad-
ministrations weekly) and group B (six administrations
weekly), according to the treatment schedule. Differ-
ences among sub-groups of age were evaluated by Fisher
exact test.
All variables were tested for normal distribution using
the Anderson-Darling normality test. All variables were
expressed as mean ± standard deviation.
Pearson product moment correlation coefficient was
employed to calculate the degree of linear correlation
between the parameters analyzed (auxological, clinical,
personal records reported in the questionnaire, hormo-
nal data).
Statistical significance was considered with p less than
0.05. Calculations were done using “MiniTAB release
13.1 Statistical Software”.
Results
Forty young patients treated with r-hGH were enrolled,
with a mean age of 11.2 + 2.3 years (Table 2). The group
of patients consisted of 27 males (67.5%) and 13 females
(32.5%). The 75% of patients were prepubertal at the
time of enrolment, whereas the 25% of cases had been
started the puberty at baseline. Twenty-six patients
showed isolated GH deficiency (65%), 9 were SGA
(22.5%) and 5 girls were affected by Turner’s syndrome
(12.5%). R-hGH treatment was started between 2.51 and
15.1 years of age (mean age 8.65 + 2.81 years).
Treatment adherence
The mean treatment adherence was 92.2% and it was in-
versely related to patients’ age (R = − 0.358, p = 0.023),
and significantly higher in sub-group of patients with
age between 10 and 13 years, compared to those with
age below 9 years or above 14 years (p < 0.001; 96.43%
versus 92.42% and 82.28%, respectively).
Treatment adherence was inversely related to the years
of therapy (R = − 0.453, p = 0.003) (Fig. 1).A higher ad-
herence was found in patients treated for 1 year (n = 13,
96.0%) and in those treated for 2–4 years (n = 17, 94.7%),
compared to patients treated for more than 4 years
(n = 10, 83.9%), although not significantly different
(p = 0.385). moreover, treatment adherence was similar
between patients who started treatment before puberty
(n = 33, 92.23%) and those who started treatment after
the puberty onset (n = 7, 92.0%) (p = 0.956).
Patients treated with injections for 6 days a week
showed a higher treatment adherence (97.26%)
compared to patients treated with injections for 7 days a
week (89.8%). The mean treatment adherence was
inversely related to the number of r-hGH doses
(R = − 0.392, p = 0.012) (Fig. 2).
Treatment efficacy
A final height increase after a mean follow-up of
2.41 + 1.86 years was detected, although not statistically
significant (p > 0.05) (Table 2). Particularly, the average
Table 2 Comparison between the parameters at the start and at the end of treatment
Baseline evaluation Follow-up evaluation p-value
Age of start therapy (years) 8.65 + 2.81 11.17 + 3.0 0.023
Years of therapy 2.41 + 1.86 –
SDS of height −2.56 + 1.10 −1.96 + 1.24 > 0.05
Growth velocity (cm/year) 4.10 + 1.17 6.76 + 3.02 0.044
Target height 160.51 + 6.64 –
Bone age (years) 7.15 + 2.84 11.44 + 4.10 0.010
IGF-1 (ng/ml) 168.20 + 99.20 320.70 + 151.20 0.032
Percentage of adherence – 92.20 + 8.90 –
Missing doses/month – 1.20 + 1.35 –
Significant entries were italicized
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height increase was 0.61 SD, ranging from − 2.56 + 1.10
SD to − 1.95 + 1.24 SD (Table 2). Moreover, a significant
growth velocity increase was demonstrated after
follow-up (p = 0.004) (Table 2). However, the height gain
was neither related to the patients’ age, nor to the age at
treatment start (R = 0.301, p = 0.059). The improvement
of height was directly related only to parental height tar-
get (R = 0.487, p = 0.002).
The treatment efficacy, considered as height gain dur-
ing r-hGH treatment, did not correlate with treatment
adherence (R = − 0.067, p = 0.683). Treatment adherence
showed a significant correlation with IGF-1 serum levels
(R = − 0.398, p = 0.032), which did not correlate with the
final height and growth velocity (R = 0.184, p = 0.340 and
R = 0.161, p = 0.422, respectively). Finally, growth vel-
ocity was directly related to treatment adherence (R =
0.325, p = 0.044) (Fig. 3), showing that children with a
higher adherence showed a higher growth velocity.
Questionnaire evaluation
The totality of parents and patients declared to receive
clear and complete information regarding the treatment
scope and modality of administration (100%). Similarly,
all patients and parents stated that easypod™ was easy to
use (100%).
Comparing the electronic evaluation of adherence,
with the questionnaire answers, 26 patients (65.0%) re-
ferred a lower number of skip doses compared to what
registered by easypod™, on the contrary 5 patients
(12.5%) referred a higher number. Thus, 9 patients
(22.5%) referred a skip doses number equal to what reg-
istered by the electronic device. In general, the mean
Fig. 1 Linear correlation between adherence and years of therapy
Fig. 2 Linear correlation between adherence (%) and the number of r-high doses
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skip doses number referred to parents was 1.3 doses
monthly, although increasing until 2.5 doses monthly
considering easypod™ data. This result suggests the
importance of use an electronic device able to object-
ive data regarding therapy compliance. Considering
the reasons for skip doses, they occurred mainly be-
cause of family journey (n = 7), followed by tiredness
(n = 6), forgetfulness (n = 5), illness (n = 5), exhaustion
needles or devices (n = 4), and technical problem to
easypod™ (n = 2). The 35% of patients treated (n = 14)
referred bother or discomfort at site of injection,
whereas only the 5% (n = 2) referred pain. The pain
degree seemed to be inversely related to the treat-
ment adherence, although not statistically significant
(R = − 0.289, p = 0.071).
The r-hGH administration was performed by patients
in 17.5% (n = 7), by parents in 65.0% (n = 26) and by
both patient and parents in 17.5% (n = 7). The adherence
was significantly lower in those patients who
self-injected r-hGH (80.9%), compared to those treated
by parents (95.2%) (p = 0.002). Only the 37.5% (n = 15)
of patients used all possible sites of injection, whereas
the 32.5% (n = 13) refused at least one site (generally
abdomen), 12.5% (n = 5) refused two sites and 17.5% (n
= 7) used only one of the possible sites of injection. The
number of refused sites of injection was inversely related
to the treatment adherence (R = − 0.520, p = 0.011)
(Fig. 4). Finally, the parents’ “level of education” did not
show a statistically significant correlation with the treat-
ment adherence.
Considering the overall satisfaction, 24 patients stated
a high satisfaction for the achieved results (60.0%). On
the contrary, 12 patients declared a mild satisfaction
(30.0%), 3 a poor satisfaction (7.5%) and only one patient
was dissatisfied by the treatment (2.5%).
Discussion
This retrospective, observational study based on real-life
data shows the experience of a single Italian Centre in
the treatment of GH deficiency in young patients using
easypod™ electronic device. The study demonstrated a
high r-hGH treatment adherence in childhood and ado-
lescence. The device automatic report shows an average
adherence of 92.2%, which is significantly higher than
the minimal percentage proposed to define the good ad-
herence to r-hGH administration (85%) [21]. Moreover,
the data registration by the electronic device allows at
demonstrating that 35% of patients erroneously relays
their treatment adherence. Thus, easypod™ allows to ob-
tain a high adherence with a low percentage of relay er-
rors. Accordingly, Bozzola et al. previously found an
average adherence to r-hGH administration of 87.5% in
824 children, with a concordance between data collected
by easypod™ and data relayed by patients/parents in the
84.3% of the cases [22]. Moreover, data from an Ameri-
can GH registry based on physician-reported adherence,
indicate that the 76–85% of patients missed 0–3 doses
per month [4]. All these results confirm the importance
to measure adherence by the electronic device, bypassing
potential relayed errors. Easypod™ represents one of the
most recent advances obtained in the field of r-hGH
therapy, which could be optimal to obtain these achieve-
ments. Moreover, all patients and parents enrolled in
this study consider the device to be quick, easy and
comfortable to use.
All the patients and the parents were encouraged to
r-hGH treatment by physicians, explaining them the bene-
fits of r-hGH treatment on growth and global health. They
were encouraged to discuss with the physicians about
their fears and troubles, linked to r-hGH treatment, at
every control visit. The impact of socioeconomic level and
Fig. 3 Correlation between growth velocity and treatment adherence
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the parents’ instruction degree, evaluated by a point ad
hoc included in the questionnaire, were minimized by the
simple language of the questionnaire and by the personal-
ized trial; the latter has been dedicated to each naïve
patient and to their parents and it was offered by a profes-
sional and specialized nurse.
Despite these improvements, the treatment adherence
is not complete, leaving challenges at identifying the
multifaceted reason for poor adherence [23].
This study confirms the difficulties to treat chronic
diseases in childhood and adolescence. However, an in-
verse relationship between adherence and patient’s age is
debated. Increasing the patient’s age, a decrease adher-
ence is found, suggesting the difficulties to manage GH
deficiency especially during adolescence. This confirms
the difficulty of adolescents to accept the idea to suffer a
chronic disease, which makes them “different” from
peers. In particular, during adolescence, patients start to
take care of their own health, they must accept their
underlying disease and they come from a long-time ther-
apy during childhood [5]. All these challenges should be
considered in the management of r-hGH treatment. In
our group, the most adherent patients belonged to the
age 10–13 years, whereas a reduced adherence found in
both older and younger patients [5]. However, the per-
centage of adherence progressively decreases, increasing
the treatment period. The treatment with the same dose,
divided into 6 days every week, seems to be better toler-
ated than a complete weekly protocol. Thus, a compre-
hensive evaluation of patients’ setting and therapeutic
schemes available should be mandatory to improve both
adherence and efficacy in clinical practice.
Several prospective interventional studies previously
demonstrated the r-hGH efficacy in idealized and rigor-
ously controlled conditions [1, 2]. However, it is well
known that interventional studies show high internal
validity, even if external one is reduced and data should
be confirmed in the clinical practice [24]. We performed
an observational study based on real-life approach to
GH deficiency in childhood and adolescence, using
real-world data, confirming the r-hGH efficacy and ef-
fectiveness, with a mean height increase of 0.60 SD com-
pared to the baseline height. Although this increase is
not statistically significant, it is in line with the definition
of a good r-hGH treatment response, which is reached
when the height increase is more than 0.3–0.5 SD [25,
26]. Thus, we confirm the efficacy of r-hGH administra-
tion in our patients with isolated GH deficiency, SGA,
chronic renal failure and Turner syndrome, even if we
cannot divide our patients in different groups, according
to the primary disease, for the numerically reduced
numbers of some subgroups. However, in our patients
the height gain is not related to treatment adherence,
differently to previous studies using easypod™ [27], al-
though it correlates with IGF-1 serum levels.
Patients started puberty at different timing of the
treatment period; some patients started at the beginning
of therapy, some patients after some years and could
have influenced the statistical significance of the height
gain during the therapy. These differences could have in-
fluenced growth in GH deficient patients, whose diagno-
sis was done in line with international protocols. All the
patients showed a pathological short stature, low growth
velocity, delayed bone age and documented by two
pathological tests (GH < 8 ng/ml).
These results could be explained by the high rates of
adherence, above 85%, found in the study, which guaran-
tees an appropriate growth velocity. Accordingly, IGF-1
significantly increased during treatment, remaining
within the normal range. The final height shows a
Fig. 4 Correlation between adherence (%) and the number of refused sites of injection
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significant correlation with target height, suggesting a
possible main role of parental height in the setting of
GH deficiency, although it is controversial in the litera-
ture. Indeed, some studies demonstrated a higher final
height after r-hGH treatment compared to the target in
congenital adrenal hyperplasia [28]. On the contrary, no
correlations were found in Prader-Willi syndrome [29].
Further studies properly designed are needed to better
understand the role of the genetic background on final
height, as shown in children with GH deficiency associ-
ated with SHOX deficiency [30].
Finally, the highest treatment adherence was reached
when the dose was provided by parents, when no pain
occurred and when all sites of injection were selected.
These results derived from questionnaire ad hoc de-
signed to screen r-hGH treatment satisfaction, suggest-
ing that parents and patients need information and
training to improve the treatment adherence. Once
again, the multifactorial characteristics of treatment ad-
herence are confirmed, in the chronic daily r-hGH ther-
apy. However, a pharmaco-economy evaluation should
be necessary in this setting, to compare the r-hGH doses
used, the missed doses and the efficacy of the treatment.
To this purpose, an electronic device able to recognise
patients with poor adherence is fundamental in the glo-
bal strategy aiming at bypassing all challenges in r-hGH
therapy.
Conclusions
The strength of our study is characterized by the evalu-
ation of both efficacy and adherence of r-hGH treatment
using a real-life monocentric approach. Moreover, the
complete evaluation of adherence using both question-
naires and electronic devices, allows at confirming the
multifactorial nature of treatment adherence.
The injection-recording system and the possibility to
monitor the real recipient of the treatment by easypod™
could enhance the ability of the physicians to monitor
adherence to r-hGH.
Furthermore, r-hGH treatment is an expensive therapy,
guaranteed in Italy by the national health system for the
treatment of the authorized diseases. This condition requires
an accurate surveillance with the finality of reducing waste
and of containing costs. These goals significantly contribute
to optimize r-hGH treatment and to allow this expensive
therapy to all the patients who need it.
The questionnaire proposed to our patients could be used
to increase surveillance on r-hGH treatment adherence and
to prevent potential causes of reduced compliance. However,
the discordance between the questionnaire answers and the
easypod™ records induce to choose the electronic device to
obtain a real report of administered doses.
However, the main limits of our study are the low
number of enrolled patients and the lack of a control
group. For the limited number of patients with diseases
other than GH deficiency, the comparison of compliance
with r-hGH treatment in subjects affected by different
diseases could not be statistically evaluated.
Moreover, both patients and parents are aware that adher-
ence is monitored during the study, and that a good adher-
ence to the therapy influences the final height. Future larger
multicentre observational trials based on real world data
should be useful to better understand and describe the
effectiveness and the adherence of r-hGH treatment.
In conclusion, easypod™ is an electronic device able to
monitor the adherence to daily r-hGH treatment in children
and adolescent with GH deficiency as well as in patients
who need other expensive treatment self-managed by the
family at home, which need adherence and surveillance.
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